524 related articles for article (PubMed ID: 1855205)
1. A potent specific pure antiestrogen with clinical potential.
Wakeling AE; Dukes M; Bowler J
Cancer Res; 1991 Aug; 51(15):3867-73. PubMed ID: 1855205
[TBL] [Abstract][Full Text] [Related]
2. ICI 182,780, a new antioestrogen with clinical potential.
Wakeling AE; Bowler J
J Steroid Biochem Mol Biol; 1992 Sep; 43(1-3):173-7. PubMed ID: 1525058
[TBL] [Abstract][Full Text] [Related]
3. MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen.
Brünner N; Boysen B; Jirus S; Skaar TC; Holst-Hansen C; Lippman J; Frandsen T; Spang-Thomsen M; Fuqua SA; Clarke R
Cancer Res; 1997 Aug; 57(16):3486-93. PubMed ID: 9270017
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer.
Robertson JF; Nicholson RI; Bundred NJ; Anderson E; Rayter Z; Dowsett M; Fox JN; Gee JM; Webster A; Wakeling AE; Morris C; Dixon M
Cancer Res; 2001 Sep; 61(18):6739-46. PubMed ID: 11559545
[TBL] [Abstract][Full Text] [Related]
5. A new antiestrogen, 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-indol-5-ol hydrochloride (ERA-923), inhibits the growth of tamoxifen-sensitive and -resistant tumors and is devoid of uterotropic effects in mice and rats.
Greenberger LM; Annable T; Collins KI; Komm BS; Lyttle CR; Miller CP; Satyaswaroop PG; Zhang Y; Frost P
Clin Cancer Res; 2001 Oct; 7(10):3166-77. PubMed ID: 11595711
[TBL] [Abstract][Full Text] [Related]
6. Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAMR-1.
Lykkesfeldt AE; Madsen MW; Briand P
Cancer Res; 1994 Mar; 54(6):1587-95. PubMed ID: 8137264
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer.
Osborne CK; Coronado-Heinsohn EB; Hilsenbeck SG; McCue BL; Wakeling AE; McClelland RA; Manning DL; Nicholson RI
J Natl Cancer Inst; 1995 May; 87(10):746-50. PubMed ID: 7563152
[TBL] [Abstract][Full Text] [Related]
8. Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer.
DeFriend DJ; Howell A; Nicholson RI; Anderson E; Dowsett M; Mansel RE; Blamey RW; Bundred NJ; Robertson JF; Saunders C
Cancer Res; 1994 Jan; 54(2):408-14. PubMed ID: 8275477
[TBL] [Abstract][Full Text] [Related]
9. Effects of a new clinically relevant antiestrogen (GW5638) related to tamoxifen on breast and endometrial cancer growth in vivo.
Dardes RC; O'Regan RM; Gajdos C; Robinson SP; Bentrem D; De Los Reyes A; Jordan VC
Clin Cancer Res; 2002 Jun; 8(6):1995-2001. PubMed ID: 12060645
[TBL] [Abstract][Full Text] [Related]
10. Progression of MCF-7 breast cancer cells to antiestrogen-resistant phenotype is accompanied by elevated levels of AP-1 DNA-binding activity.
Dumont JA; Bitonti AJ; Wallace CD; Baumann RJ; Cashman EA; Cross-Doersen DE
Cell Growth Differ; 1996 Mar; 7(3):351-9. PubMed ID: 8838865
[TBL] [Abstract][Full Text] [Related]
11. Bioactivities, estrogen receptor interactions, and plasminogen activator-inducing activities of tamoxifen and hydroxy-tamoxifen isomers in MCF-7 human breast cancer cells.
Katzenellenbogen BS; Norman MJ; Eckert RL; Peltz SW; Mangel WF
Cancer Res; 1984 Jan; 44(1):112-9. PubMed ID: 6537799
[TBL] [Abstract][Full Text] [Related]
12. ICI 164,384, a pure antagonist of estrogen-stimulated MCF-7 cell proliferation and invasiveness.
Thompson EW; Katz D; Shima TB; Wakeling AE; Lippman ME; Dickson RB
Cancer Res; 1989 Dec; 49(24 Pt 1):6929-34. PubMed ID: 2582435
[TBL] [Abstract][Full Text] [Related]
13. Antiestrogenic potency and binding characteristics of the triphenylethylene H1285 in MCF-7 human breast cancer cells.
Sheen YY; Ruh TS; Mangel WF; Katzenellenbogen BS
Cancer Res; 1985 Sep; 45(9):4192-9. PubMed ID: 4040807
[TBL] [Abstract][Full Text] [Related]
14. Tamoxifen-resistant fibroblast growth factor-transfected MCF-7 cells are cross-resistant in vivo to the antiestrogen ICI 182,780 and two aromatase inhibitors.
McLeskey SW; Zhang L; El-Ashry D; Trock BJ; Lopez CA; Kharbanda S; Tobias CA; Lorant LA; Hannum RS; Dickson RB; Kern FG
Clin Cancer Res; 1998 Mar; 4(3):697-711. PubMed ID: 9533540
[TBL] [Abstract][Full Text] [Related]
15. Structure-activity relationships of nonisomerizable derivatives of tamoxifen: importance of hydroxyl group and side chain positioning for biological activity.
Murphy CS; Parker CJ; McCague R; Jordan VC
Mol Pharmacol; 1991 Mar; 39(3):421-8. PubMed ID: 2005879
[TBL] [Abstract][Full Text] [Related]
16. Effects of 4-hydroxytamoxifen and a novel pure antioestrogen (ICI 182780) on the clonogenic growth of human breast cancer cells in vitro.
DeFriend DJ; Anderson E; Bell J; Wilks DP; West CM; Mansel RE; Howell A
Br J Cancer; 1994 Aug; 70(2):204-11. PubMed ID: 8054267
[TBL] [Abstract][Full Text] [Related]
17. Antiestrogen binding in antiestrogen growth-resistant estrogen-responsive clonal variants of MCF-7 human breast cancer cells.
Miller MA; Lippman ME; Katzenellenbogen BS
Cancer Res; 1984 Nov; 44(11):5038-45. PubMed ID: 6488162
[TBL] [Abstract][Full Text] [Related]
18. Tamoxifen exerts agonistic effects on clusterin and complement C3 gene expression in RUCA-I primary xenografts and metastases but not normal uterus.
Zierau O; O'Sullivan J; Morrissey C; McDonald D; Wünsche W; Schneider MR; Tenniswood MP; Vollmer G
Endocr Relat Cancer; 2004 Dec; 11(4):823-30. PubMed ID: 15613455
[TBL] [Abstract][Full Text] [Related]
19. Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice.
Osborne CK; Hobbs K; Clark GM
Cancer Res; 1985 Feb; 45(2):584-90. PubMed ID: 3967234
[TBL] [Abstract][Full Text] [Related]
20. Association of interferon regulatory factor-1, nucleophosmin, nuclear factor-kappaB, and cyclic AMP response element binding with acquired resistance to Faslodex (ICI 182,780).
Gu Z; Lee RY; Skaar TC; Bouker KB; Welch JN; Lu J; Liu A; Zhu Y; Davis N; Leonessa F; Brünner N; Wang Y; Clarke R
Cancer Res; 2002 Jun; 62(12):3428-37. PubMed ID: 12067985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]